Capital dedicated by local investors to risky investments that was once largely tied up in junior explorers is starting to flow to early-stage biotech companies, according to stockbrokers and fund managers.

The momentum behind local biotech and medtech giants such as CSL, Cochlear and ResMed is filtering downstream, with investors hunting for companies that could go on to have similar success in the decades to come.